Pharmacogenomics Seen Growing to $6B by 2005, Report Says | GenomeWeb

NEW YORK, July 3 – The pharmacogenomics market is expected to grow to more than $6 billion by 2005, compared with $1.7 billion in 2000, consulting firm Frost & Sullivan said Tuesday in a report.

The figures for the pharmacogenomics market reflect actual and anticipated revenues stemming from services, gene-based diagnostics, and orphan drugs.

Yet, despite the strong growth outlook, Frost & Sullivan said that ethical debates could put a damper on growth, particularly in diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.